A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Phase of Trial: Phase III
Latest Information Update: 20 Feb 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms DECISION
- Sponsors Bayer; Bayer HealthCare
- 02 Dec 2017 This trial was completed in Sweden (end date: 30/08/2017), according to European Clinical Trials Database.
- 02 Dec 2017 This trial was completed in Netherlands, according to European Clinical Trials Database.
- 29 Nov 2017 This trial was completed in Belgium (End date: 2017-08-30), according to the European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History